Network pharmacology identified active alkaloids and 194 overlapping targets associated with NAFLD, and protein-protein interaction analysis highlighted TP53, EGFR, STAT3, AKT1, and TNF as key hub genes. This evidence concerns the gene AKT1 and metabolic dysfunction-associated steatotic liver disease.